MedMira Inc
XTSX:MIR
Intrinsic Value
MedMira, Inc. is a biotechnology company, which through its subsidiaries, engages in the research, development, manufacture, and commercialization of diagnostics and technology platforms. [ Read More ]
The intrinsic value of one MIR stock under the Base Case scenario is 0.002 CAD. Compared to the current market price of 0.09 CAD, MedMira Inc is Overvalued by 98%.
Valuation Backtest
MedMira Inc
Run backtest to discover the historical profit from buying and selling MIR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
MedMira Inc
Current Assets | 2.6m |
Cash & Short-Term Investments | 853.8k |
Receivables | 1.4m |
Other Current Assets | 319.9k |
Non-Current Assets | 1.9m |
PP&E | 1.9m |
Current Liabilities | 17.9m |
Accounts Payable | 3.2m |
Accrued Liabilities | 2.9m |
Short-Term Debt | 2.9m |
Other Current Liabilities | 8.9m |
Non-Current Liabilities | 2.6m |
Long-Term Debt | 2.6m |
Other Non-Current Liabilities | -10 |
Earnings Waterfall
MedMira Inc
Revenue
|
407.8k
CAD
|
Cost of Revenue
|
-156.8k
CAD
|
Gross Profit
|
251k
CAD
|
Operating Expenses
|
-2.4m
CAD
|
Operating Income
|
-2.2m
CAD
|
Other Expenses
|
-737.9k
CAD
|
Net Income
|
-2.9m
CAD
|
Free Cash Flow Analysis
MedMira Inc
MIR Profitability Score
Profitability Due Diligence
MedMira Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
MedMira Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
MIR Solvency Score
Solvency Due Diligence
MedMira Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
MedMira Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MIR Price Targets Summary
MedMira Inc
Shareholder Return
MIR Price
MedMira Inc
Average Annual Return | 582.08% |
Standard Deviation of Annual Returns | 1 147.17% |
Max Drawdown | -91% |
Market Capitalization | 63.2m CAD |
Shares Outstanding | 697 445 660 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MedMira, Inc. is a biotechnology company, which through its subsidiaries, engages in the research, development, manufacture, and commercialization of diagnostics and technology platforms. The company is headquartered in Halifax, Nova Scotia. The firm is engaged in the development and commercialization of rapid diagnostics and technology platforms. The MedMira Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its technology platform detects multiple biomarkers specific to several diseases using a single cartridge. Its Multiplo line of rapid tests for human immunodeficiency virus (HIV), Hepatitis B and C, and syphilis uses the platforms capabilities to deliver approximately up to four test results using one test cartridge and one drop of specimen. The company also has a research product line that facilitates technology licensing, contract manufacturing, and regulatory consulting. The firm sells its rapid tests through a network of medical distributors and strategic business development partners to customers in all sectors of the healthcare industry, including laboratories, hospitals and point-of-care clinics, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one MIR stock under the Base Case scenario is 0.002 CAD.
Compared to the current market price of 0.09 CAD, MedMira Inc is Overvalued by 98%.